Navigation Links
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™(*)) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity
Date:10/5/2011

nomide compared to placebo. No serious or opportunistic infections and no deaths occurred in trial participants treated with teriflunomide.  The proportion of participants who discontinued the study medication because of disease progression was significantly smaller in the group receiving the 14mg of teriflunomide than in the placebo group (p=0.02). Malignancies were reported in three participants in the placebo group and one in the teriflunomide 14mg group.

Teriflunomide adverse events were usually of mild to moderate intensity, managed with existing therapies and rarely led to treatment discontinuation. The most common were diarrhea, nausea, liver enzyme increases (that were mainly mild and asymptomatic with no dose effect) and mild hair thinning/decreased hair density. In general, diarrhea, nausea and alopecia, were mild to moderate, transient, and infrequently led to treatment discontinuation.

About Teriflunomide
Teriflunomide is an immunomodulatory, disease-modifying oral drug with anti-inflammatory properties, and is under investigation for the treatment of MS. Teriflunomide blocks the proliferation and functioning of activated T and B  lymphocytes - which are thought to be especially damaging in MS - by selectively and reversibly inhibiting a critical mitochondrial enzyme. Slowly dividing or resting lymphocytes are unaffected by teriflunomide, leaving the immune system's response to infection uncompromised. With nine years of continuous use in a Phase II extension, teriflunomide has the longest clinical experience of any investigational oral MS therapy. In addition to the TEMSO trial, two other Phase III trials, TOWER and TENERE, are ongoing in people with RMS. A Phase III study, TOPIC, is also underway in early MS or CIS (clinically isolated syndrome). Teriflunomide is also being evaluated as an adjunct therapy to interferon-beta in the Phase III TERACLES trial.

(*) Aubagio™ is the registered name submitted to
'/>"/>

SOURCE Sanofi; Genzyme
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
2. Positive Phase III Data on Bayers Investigational Drug Radium-223 Chloride Show Significant Increase in Overall Survival
3. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
4. Bayer to Present New Data Evaluating Investigational Oncology Compounds at 2011 ECCO-ESMO Congress
5. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
6. FDA Grants Fast Track Designation to Bayers Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
7. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
8. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
9. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
10. Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Associations 71st Annual Scientific Sessions
11. Morphotek, Inc. Announces That Two Investigational Drugs Have Received Orphan Drug Designations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015 Precyse, a leader in health information ... as part of its long term growth plan, the ... by investment firm Pamplona Capital Management (Pamplona).  Precyse,s board ... Partners and NewSpring Capital, have approved this corporate transaction. ... 5,000 healthcare facilities and systems across the ...
(Date:7/1/2015)... Research and Markets( ... "2015 Strategies in the Home/Self Testing Market" ... new 175-page report provides analysis of the major ... meters), pregnancy, ovulation, and occult blood. The report ... and competitive profiles. The growing economic ...
(Date:7/1/2015)... 2015 Dynatronics Corporation (the "Company") (NASDAQ: ... rehabilitation and physical therapy products, announced today that ... led by affiliates of Prettybrook Partners LLC (collectively, ... the healthcare industry. The financing provides Dynatronics with ... potential strategic acquisitions.  "We enthusiastically ...
Breaking Medicine Technology:Precyse Enters into Acquisition Agreement with Pamplona Capital Management 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 32015 Strategies in the Home/Self Testing Market 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 3
... YORK, Aug. 31 /PRNewswire/ Reportlinker.com announces that a ... catalogue: Hormone Replacement Therapy in ... 2017 http://www.reportlinker.com/p0254468/Hormone-Replacement-Therapy-in-Menopause---Pipeline-Assessment-and-Market-Forecasts-to-2017.html ... Assessment and Market Forecasts to 2017 ...
... 31 Reportlinker.com announces that a new market ... The Outlook for Pharmaceuticals In The ... http://www.reportlinker.com/p0285781/The-Outlook-for-Pharmaceuticals-In-The-Middle-East-And-North-Africa-To-2015.html ... social and demographic development is making the pharmaceutical ...
Cached Medicine Technology:Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 2Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 3Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 4Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 5Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 6Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 7Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 8Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 9Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 10Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 11Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 12Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 13Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 14
(Date:7/2/2015)... ... 2015 , ... Denver-based SlimGenics Weight Control Centers, the leader ... 14 on ColoradoBiz magazine’s Top 100 Woman-Owned Companies list. ColoradoBiz compiles the exclusive ... award identifies outstanding woman-owned businesses that demonstrate excellence and success in the industry ...
(Date:7/1/2015)... ... 2015 , ... With all final regulatory approvals in place ... N.Y., is now a member of national system Trinity Health, effective immediately. ... committed to delivering high-value care, said Richard J. Gilfillan, M.D., president and CEO, ...
(Date:7/1/2015)... ... 01, 2015 , ... For decades, researchers in the genetics field have theorized ... brain, never changing after development in the womb. Now, researchers from the Icahn School ... cells throughout life – a process which helps to switch genes on and off. ...
(Date:7/1/2015)... ... 01, 2015 , ... Ormco Corporation, a leading manufacturer and ... Smile for a Lifetime Foundation (S4L) fundraising event held at the 14th Annual ... S4L in its mission to provide free quality orthodontic care to individuals with ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Collaborative for Children and ... Community Trust. The grant will allow CCF to improve quality of care and save ... was formed to respond to many changes in New York’s Medicaid system. Experts agree ...
Breaking Medicine News(10 mins):Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 3Health News:St. Joseph’s Health Now a Member of Trinity Health 2Health News:St. Joseph’s Health Now a Member of Trinity Health 3Health News:St. Joseph’s Health Now a Member of Trinity Health 4Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3
... 02, 2009 The antiepileptic drug vigabatrin (VGB) has been ... special form of epilepsy in infants, called infantile spasm. However, ... has been shown to cause a permanent narrowing of visual ... exposed at school age or later. A new study published ...
... U.S. Ambassador to the United Republic of Tanzania, joins Malaria ... No More Policy Center in Washington, DC, the non-profit organization ... fight against malaria in Africa to his new role at ... advocacy work to engage policymakers in the race to save ...
... given awayFORT WORTH, Texas, Feb. 2 ... USA announces the launch of the second season ... 26, 2009, Marinela USA consumers can collect one ... specially marked boxes of Barritas Fresa, Barritas Pina, ...
... and only multi-module training program devoted exclusively to whiplash ... Stutzman, local Doctor of Chiropractic practicing in Paoli, PA ... specifically to whiplash and brain injury traumatology. The ... prestigious Spine Research Institute of San Diego . ...
... Danaher Corporation (NYSE: DHR ) announced ... L. Comas will be presenting at the Barclays Capital ... 9, 2009 at 1:35 p.m. EST. The audio will ... of the webcast will be available for one week ...
... Digirad Corporation (Nasdaq: DRAD ), a ... equipment leasing services that improve patient care while driving ... the assets related to three northern California service hub ... Fe, Calif.-based MD Office Solutions calls for the sale ...
Cached Medicine News:Health News:Controversial medication may decrease spasms for infants with epilepsy 2Health News:Recent U.S. Ambassador to Tanzania Mark Green Named Managing Director of Malaria No More Policy Center 2Health News:Marinela USA(R) Recharges ZumbAtomic for Second Season 2Health News:Local Chiropractic Doctor Graduates from Elite Whiplash Trauma Training Program Led by International Scientific Authority, Dr. Arthur Croft 2Health News:Local Chiropractic Doctor Graduates from Elite Whiplash Trauma Training Program Led by International Scientific Authority, Dr. Arthur Croft 3Health News:Digirad Corporation Sells Northern California Service Hubs 2
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
The Trident PSL Acetabular Shells are designed to maximize fixation in the peripheral lunate region of the acetabulum....
The Trident ceramic acetabular system provides several important benefits and meets greater demands of younger, more active patients....
Medicine Products: